How Inizio Ignite helps clients navigate uncertainty in the life sciences sector

With more than 10,500 experts in over 50 countries, Inizio brings together scientific, medical, commercial, analytics and technology capabilities. Remco op den Kelder, group president at Inizio Ignite, explains the key trends the firm is helping its clients adapt to, amid a changing AI-ready market.

As the commercialisation journey becomes more complex, what do you think companies need to make better, more connected decisions?

One of the biggest shifts I’ve seen is that commercialisation has become much less linear. It used to be possible to move from development to launch with a relatively predictable set of assumptions. Today, those assumptions are changing constantly. Scientific innovation is accelerating, payer expectations are evolving, AI is changing how organisations work, and patients are entering increasingly complex care pathways.

The challenge isn’t simply managing more complexity. It’s preventing that complexity from creating fragmentation. Too often, commercial, medical, market access, and strategy teams are making good decisions independently, but they’re not always making connected decisions together.

The organisations pulling ahead are creating environments where information moves quickly across functions, leaders have a shared view of success, and teams are empowered to adapt without losing sight of the overall strategy. That’s a fundamentally different operating model than many companies have relied on historically.

Going forward, I believe competitive advantage will belong to organisations that connect decisions – not just data. The companies that can align people, insights, and execution around a common purpose will be much better positioned to respond as markets continue to evolve.

How do you see AI transforming the way life sciences organi s ations engage scientific, medical and commercial stakeholders?

I think we’re moving beyond asking whether AI has a role in life sciences. The more interesting question is how organisations redesign the way they work because AI is available.

For me, AI isn’t about replacing expertise. Scientific, medical, and commercial decisions will always require human judgment. What AI changes is the speed at which people can understand what’s happening, identify meaningful patterns, and respond with confidence.

Historically, organisations often looked backward to understand performance. Today, AI allows teams to learn while they’re executing. Whether it’s understanding how healthcare professionals are responding to messaging, identifying emerging barriers to adoption, or helping field teams continuously improve, AI has the potential to create much tighter feedback loops.

The organisations that will create the most value won’t necessarily be those investing in the most AI. They’ll be the ones that successfully integrate AI into workstreams so it becomes part of how the organisation learns, collaborates, and continuously improves.

What are the biggest challenges companies face before launch, and how can they set themselves up for commercial success?

One mistake I still see is organisations thinking about launch as something that begins shortly before approval. In reality, commercial success is shaped years earlier.

Today’s products are entering increasingly specialised markets with more stakeholders, greater access complexity, and higher expectations around evidence generation. That means companies need to start thinking much earlier — not just about the product itself, but about the system it’s entering.

Organisational readiness has become just as important as scientific readiness. Are teams aligned around a common vision? Are they making decisions quickly? Do they understand the patient journey, the payer environment, and how those realities may change before launch?

The strongest organisations also recognise that flexibility is becoming a strategic capability. Rather than building a detailed plan and hoping reality follows it, they’re creating operating models that allow them to learn continuously and adjust as new information becomes available.

In today’s environment, launch readiness isn’t about having every answer. It’s about building an organisation that’s prepared to respond when the answers change.

Why are product launches becoming more patient-led, and how is that changing launch strategy?

Healthcare has become far more personalised, and launch strategy is evolving alongside it. Increasingly, success depends not just on having differentiated science, but on understanding how patients actually experience care.

When therapies target smaller or more specialised populations, every step of the patient journey matters. Diagnosis, referral patterns, access, reimbursement, education, and ongoing support all influence whether patients ultimately receive treatment. Those aren’t operational details anymore – they’re central to commercial strategy.

As a result, we’re seeing launch planning become much more patient-centered. Organisations are spending more time understanding care pathways, engaging a broader group of stakeholders, and thinking earlier about where friction exists within the healthcare system.

I think that’s a positive shift. Designing launches around the realities of patient care doesn’t just improve the patient experience – it also creates stronger commercial outcomes because organisations are solving real barriers to adoption instead of assuming the market will behave as expected.

Inizio Ignite recently supported more than 10 concurrent product launches. What are the biggest lessons about what separates successful launches from those that fall short?

Working across multiple launches reinforces one lesson again and again: success rarely comes down to the product alone. Most organisations we’re working with have compelling science. What separates the strongest launches is how the organisation responds when conditions inevitably change.

Those conditions can shift for any number of reasons - changes in access and policy, geopolitical shifts, increasing scientific complexity, and competitor activity can quickly alter the assumptions on which a launch strategy was built. As a result, even a strong strategy cannot remain static. The teams that maintain momentum are those that recognise shifts early, understand what they mean for the launch, and adapt their approach accordingly.

The best teams don’t assume their original plan is perfect. They create a culture where people surface issues early, share information openly, and make decisions quickly. They recognise that launch is a period of continuous learning, not simply execution.

Another lesson is that alignment matters far more than perfection. When leadership, commercial, medical, market access, and field teams are all working toward the same objectives, organisations can adjust much faster without creating confusion.

Finally, successful launches treat performance as something to actively manage rather than simply measure. They ask not only "What happened?" but "What are we learning, and what should we do differently next?"

Looking ahead, how do you see the commercialisation landscape evolving, and how is Inizio Ignite positioning itself to help clients succeed?

I believe we’re entering a period where commercialisation will become increasingly connected. The traditional boundaries between strategy, commercial execution, medical affairs, AI, analytics, and organisational transformation are beginning to disappear because clients no longer experience those challenges separately.

At the same time, the pace of change continues to accelerate. Organisations are managing more complex science, greater pricing and access pressures, rapidly advancing technology, and evolving expectations from healthcare professionals and patients. That environment requires a different way of operating.

What I hear consistently from clients is that they don’t need another specialist advisor. They need a partner who understands how all of those pieces fit together and can help translate complexity into action. That’s exactly how we’ve built Inizio Ignite. We’ve brought together deep scientific, commercial, strategic, and AI expertise because we believe the future belongs to organisations that make connected decisions rather than isolated ones.

Ultimately, our role is simple: help clients navigate uncertainty with confidence so they can bring innovation to patients faster, more effectively, and with greater impact.